Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.27

Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.
Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.
Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-113299
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2025-05-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.997803+00:00
generated_at: 2026-05-22T13:45:33.541732+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-113299
json_url: https://secwatch.observer/filing/0001193125-25-113299.json
markdown_url: https://secwatch.observer/filing/0001193125-25-113299.md
text_url: https://secwatch.observer/filing/0001193125-25-113299.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/0001193125-25-113299-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/d923057d8k.htm
generated_by_model: deepseek-v4-flash:cloud
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-113299

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.